


Transaction Overview



Syneos Health announced that it has acquired Kinapse on August 20th, 2018

- Syneos is funding the transaction through cash on hand; financial terms of the transaction were not disclosed
- The transaction is expected to be accretive to the Syneo's earnings per share
- Syneos remains committed to achieving a net leverage ratio of approximately 3.0x by the end of 2019
- On the day of the announcement, Syneos stock rose 1% and in the week following the announcement rose as much as 6%

Syneos Health (NASDAQGS: SYNH) Stock Performance Year-To-Date



Notable Commentary



"As customers increasingly face risk, competition and rising development costs, the innovative, technology-enabled solutions provided by Kinapse are seeing increasing demand. Through this combination we continue to inject new and enriched high-value solutions into the industry's only end-to-end offering, unlocking value for all of our biopharmaceutical customers. Additionally, with Kinapse's growth, recurring revenue streams and new cross-selling opportunities, we're poised to further strengthen our Commercial business."

- Alistair Macdonald, CEO Syneos Health



"We've been following Syneos Health as the Company has forged a new model for accelerating therapies to market, and we look forward to adding further depth to its end-to-end offering. We see growth opportunities driven by the integration of our solutions and the ability to tap into Syneos Health's broad customer base."

- Dawn Marriot-Sims, Executive Chairman Kinapse

Overview of Kinapse

- Provides consulting and outsourcing services to life sciences organizations and their customers, suppliers, and regulators
- The company also offers services in the areas of quality and compliance, medical affairs, development operations, clinical operations, market access, life sciences policy, pharmacovigilance and drug safety, regulatory affairs, medical writing, and medical information
- Founded in 2005, Kinapse works with small to mid and large biopharmaceutical companies – including many of the top 20 global biopharma companies – and has more than 600 employees across the United Kingdom, India and the United States